Laser and eye drop combo may offer new hope for baby tumors

NCT ID NCT07560332

First seen May 06, 2026 · Last updated Jun 23, 2026 · Updated 8 times

Summary

This study compared two treatments for infantile hemangioma, a common benign tumor in children. One group received oral propranolol daily for 3 months, while the other had weekly fractional CO2 laser sessions followed by topical timolol drops. The trial enrolled 30 children aged 1 month to 12 years and measured improvement using a global assessment score. The goal was to see if the laser-and-drop approach works as well as the oral medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFANTILE HEMANGIOMA (IH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cairo University

    Cairo, 11562, Egypt

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

propranolol (oral) and timolol (topical)

What this could lead to

If successful, this could show that laser-assisted topical timolol is as effective as oral propranolol, offering a less invasive treatment option for infantile hemangioma.

What could go wrong

This is a small, completed trial with only 30 participants, so results may not apply broadly. Both treatments have known side effects, and the laser procedure may cause discomfort or scarring.

Conditions

The condition(s) this trial relates to.

capillary hemangioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.